Citrix Systems Inc
Change company Symbol lookup
Select an option...
CTXS Citrix Systems Inc
RAKR Rainmaker Worldwide Inc
CLB Core Laboratories NV
KERN Akerna Corp
T AT&T Inc
YPPN Yappn Corp
RUSHB Rush Enterprises Inc
CMTL Comtech Telecommunications Corp
BMYMP Bristol-Myers Squibb Co
GOOG Alphabet Inc
Go

Information Technology : Software | Mid Cap Blend
Company profile

Citrix Systems, Inc. offers Enterprise and Service Provider products, which include Workspace Services solutions and Delivery Networking products. The Company's Enterprise and Service Provider products include Cloud Services solutions, and related license updates and maintenance, support and professional services. The Company's NetScaler nCore Technology is an architecture that enables execution of multiple packet engines in parallel. The Company's workspace services include Application Virtualization and virtual desktop infrastructure (VDI), Enterprise Mobility Management and Citrix Workspace Suite. The Company's NetScaler ADC is a software-defined application delivery controller (ADC) and load balancer. The Company's Cloud Services include ShareFile and Citrix Cloud. It provides various ways for customers to receive upgrades, support and maintenance for products, which include Software Maintenance, Subscription Advantage, Technical Support Services and Hardware Maintenance.

Premarket

Last Trade
Delayed
$137.14
0.7829 (0.57%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$136.36
Day's Change
0.00 (0.00%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
4,636

10-day average volume:
1,164,498
4,636

Tauriga Sciences, Inc. Expands its Business Capabilities Through Approval From Square Inc.

10:50 am ET August 17, 2020 (Globe Newswire) Print

EQNX::TICKER_START (Other OTC:TAUG), EQNX::TICKER_END

The Company's Capabilities Now Include Mobile Payment Processing - Point of Sale / Tradeshows / Events

via NEWMEDIAWIRE -- Tauriga Sciences, Inc. (OTCQB: TAUG) ("Tauriga" or the "Company"), a revenue generating, diversified life sciences company, with a proprietary line of functional "supplement" chewing gums (Flavors: Pomegranate, Blood Orange, Peach-Lemon, Pear Bellini, Mint, Black Currant) as well as two ongoing Biotechnology initiatives, today announced the approval from Square Inc. ("Square") to process multiple types of financial transactions. The Company's business capabilities have now expanded to include mobile payment processing and mobile Point of Sale ("mPOS").

ABOUT TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is a revenue generating, diversified life sciences company, engaged in several major business activities and initiatives. The company manufactures and distributes several proprietary retail products and product lines, mainly focused on the Cannabidiol ("CBD") and Cannabigerol ("CBG") Edibles market segment. The main product line, branded as Tauri-Gum(TM), consists of a proprietary supplement chewing gum that is both Kosher certified and Vegan formulated (CBD Infused Tauri-Gum(TM) Flavors: Mint, Blood Orange, Pomegranate) & (CBG Infused Tauri-Gum(TM) Flavor: Peach-Lemon). The Company's commercialization strategy consists of a broad array of retail customers, distributors, and a fast-growing E-Commerce business segment (E-Commerce website: www.taurigum.com). Please visit our corporate website, for additional information, as well as inquiries, at www.tauriga.com

Complementary to the Company's retail business, are its two ongoing biotechnology initiatives. The first one relates to the development of a Pharmaceutical grade version of Tauri-Gum(TM), for nausea regulation (specifically designed to help patients that are subjected to ongoing chemotherapy treatment). On March 18, 2020, the Company announced that it filed a provisional U.S. patent application covering its pharmaceutical grade version of Tauri-Gum(TM). The Patent, filed with the U.S.P.T.O. is Titled "MEDICATED CBD COMPOSITIONS, METHODS OF MANUFACTURING, AND METHODS OF TREATMENT". The second one relates to a collaboration agreement with Aegea Biotechnologies Inc. for the co-development of a rapid, multiplexed, Novel Coronavirus (COVID-19) test with superior sensitivity and selectivity.

The Company is headquartered in New York City and operates a regional office in Barcelona, Spain. In addition, the Company operates a full time E-Commerce fulfillment center located in LaGrangeville, New York.

DISCLAIMER -- Forward-Looking Statements

This press release contains certain "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 which represent management's beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as "may," "will," "expects," "anticipates," believes, "hopes," "believes," or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management's present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the "Risk Factors" section of Tauriga's Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

Contact:

CONTACT INFORMATION

Tauriga Sciences, Inc.

555 Madison Avenue, 5th Floor

New York, NY 10022

Chief Executive Officer

Mr. Seth M. Shaw

Email: sshaw@tauriga.com

cell # (917) 796 9926

Instagram: @taurigum

Twitter: @SethMShaw

Corp. Website: www.tauriga.com

E-Commerce Website: www.taurigum.com

https://ml.globenewswire.com/media/67749574-3cc1-424f-b1c4-16afe3aa6c66/small/tauringascienceslogo2-jpg.jpg

comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.